Novo Nordisk (NVO) said Friday its phase 3b trial comparing subcutaneous semaglutide 7.2 mg with semaglutide 2.4 mg and placebo achieved its primary endpoint by demonstrating a "statistically significant and superior" weight loss at week 72.
The trial, which involved 1,407 adults with obesity, showed participants administered with semaglutide 7.2 mg on a weekly basis alongside lifestyle interventions achieved a 20.7% weight loss from a mean baseline weight of 113 kg. This compares to a 17.5% reduction with semaglutide 2.4 mg and 2.4% with placebo.
The trial demonstrated that 33.2% of participants receiving semaglutide 7.2 mg achieved at least 25% weight loss, outperforming the 16.7% with semaglutide 2.4 mg and 0% with placebo.
Novo Nordisk said the semaglutide 7.2 mg demonstrated a safe and well-tolerated profile, with most adverse events being mild to moderate gastrointestinal issues that diminished over time.
Novo Nordisk shares were 2.5% lower in premarket trading.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。